Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review

Abstract

Background and objective: Changes in cannabis legalization regimes in several countries have influenced the diversification of cannabis use. There is an ever-increasing number of cannabis forms available, which are gaining popularity for both recreational and therapeutic use. From a therapeutic perspective, oral cannabis containing Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is a promising route of administration but there is still little information about its pharmacokinetics (PK) effects in humans. The purpose of this systematic review is to provide a general overview of the available PK data on cannabis and THC after oral administration. Materials and Methods: A search of the published literature was conducted using the PubMed database to collect available articles describing the PK data of THC after oral administration in humans. Results: The literature search yielded 363 results, 26 of which met our inclusion criteria. The PK of oral THC has been studied using capsules (including oil content), tablets, baked goods (brownies and cookies), and oil and tea (decoctions). Capsules and tablets, which mainly correspond to pharmaceutical forms, were found to be the oral formulations most commonly studied. Overall, the results reflect the high variability in the THC absorption of oral formulations, with delayed peak plasma concentrations compared to other routes of administration. Conclusions: Oral THC has a highly variable PK profile that differs between formulations, with seemingly higher variability in baked goods and oil forms. Overall, there is limited information available in this field. Therefore, further investigations are required to unravel the unpredictability of oral THC administration to increase the effectiveness and safety of oral formulations in medicinal use.

Brugada Electrocardiogram Pattern Induced by Recreational Delta-8-Tetrahydrocannabinol (THC): A Case Report

“…The exact mechanism of BEP remains speculative, as it has previously been attributed to either defect in cardiac ion channels resulting in depolarization/repolarization or abnormal expression of neural crest cells [ 13 ]. Our patient demonstrated reversible BEP after ingestion of delta-8 THC, which raises concerns about the safety profile of delta-8 THC.…”

Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review

“…As represented in Figure 2D , there is a clear difference in the duration of neurocognitive impairment depending on the route of administration (smoked vs. sublingual spray vs. oils). Due to differences in absorption and metabolism, THC has a different onset and duration of action depending on where in the body it is administered ( 57 – 59 ). Cannabis oils may provide up to 8 h of symptom relief due to gradual absorption of THC from the gut combined with first pass metabolism conversion of THC to 11-OH-THC, another active compound, in the liver ( 30 , 58 ).…”

Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response

“…The major cannabinoids are substrates for numerous metabolic enzymes, such as cytochrome P450 metabolizing enzymes ( 6 ). The PK of oral THC shows marked variability, with differences between formulations, for example, higher variability in baked goods and oil forms ( 14 ). The preparation method significantly impacts the final product characteristics ( 15 ).…”